Table 5 Evaluation of the predictive value of clinical factors and biomarkers for the treatment effect in terms of PFS
Parameters | p-value of the interaction term treatment arm x factora |
|---|---|
Clinical characteristics | |
Location | 0.26 |
Medical history | 0.29 |
Baseline biomarkers | |
Human FGF (pg/mL) | 0.28 |
PlGF (pg/mL) | 0.57 |
SCF sR/c-kit (ng/mL) | 0.27 |
sE-Selectin (ng/mL) | 0.48 |
TSP-1 (μg/mL) | 0.06 |
VEGF (ng/mL) | 0.82 |
VEGF-C (ng/mL) | 0.77 |
Variation (D8-D1) | |
Human FGF (pg/mL) | 0.60 |
PlGF (pg/mL) | 0.67 |
SCF sR/c-kit (ng/mL) | 0.60 |
sE-Selectin (ng/mL) | 0.62 |
TSP-1 (μg/mL) | 0.28 |
VEGF (ng/mL) | 0.45 |
VEGF-C (ng/mL) | 0.93 |